References
- Hide M, Morita E, Furukawa F, Shiobara T, Soma Y, Kameyoshi R, et al. The guidelines for the management of urticaria. Nihon Hifuka Gakkai Zasshi. 2011;121(7):1339–1388.
- Akiba Y, Kanuitz JD. Lafutidine, a protective H2 receptor antagonist, enhances mucosal defense in rat esophagus. Dig Dis Sci. 2010;55:3063–3069.
- Kanbe N, Miyachi Y. Validating of the combination therapy with a histamine H2−receptor antagonist for chronic urticaria. Rinsyo hifuka. 2004;58:1204–1206.
- Monroe EW, Cohen SH, Kalbfleisch J, Schulz CI. Combined H1 and H2 antihistamine therapy in chronic urticaria. Arch Dermatol. 1981;117:404–407.
- Paul E, Bödeker RH. Treatment of chronic urticaria with terfenadine and ranitidine: a randomized double-blind study in 45 patients. Eur J Clin Pharmacol. 1986;31:277–280.
- Bleehen SS, Thomas SE, Greaves MW, Newton J, Kennedy CT, Hindley F, et al. Cimetidine and chlorpheniramine in the treatment of chronic idiopathic urticaria: a multicentre randomized double-blind study. Br J Dermatol. 1987;117:81–88.
- Commens CA, Greaves MW. Cimetidine in chronic idiopathic urticaria: a randomized double-blind study. Br J Dermatol. 1978;99:675–679.
- Cook LJ, Shuster S. Lack of effect of cimetidine in chronic-idiopathic urticaria. Acta Derma Venercol. 1983;63:265–267.
- Simons FE, Sussman GL, Simons KJ. Effect of the H2-antagonist cimetidine on the pharmacokinetics and pharmacodynamics of the H1-antagonists hydroxyzine and cetirizine in patients with chronic urticaria. J Allergy Clin Immunol. 1995;95:685–693.
- Tani N. Comparison of gastric secretion inhibitors – the result of gastric pH monitoring test for 24 hours. Pharma Medica. 2001;19:189–199.
- Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau AM, et al. EAACI/GA2LEN/EDF/WAO guideline: management of urticaria. Allergy. 2009;64:1427–1443.